12th International Congress on Myeloproliferative Neoplasms

 

12th International Congress on Myeloproliferative Neoplasms
J

28 y/o Female w/ Well-Differentiated Systemic Mastocytosis: Imatinib for Juxtamembrane / Wild-Type KIT Variants, and Well-Differentiated

By 12th International Congress on Myeloproliferative Neoplasms FEATURING Jason R. Gotlib
By 12th International Congress on Myeloproliferative Neoplasms FEATURING Jason R. Gotlib
0 views
November 25, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison
Cases
06:02
12th International Congress on Myeloproliferative Neoplasms

66 y/o Female w/ Aggressive Systemic Mastocytosis: AHNs Are Under-Di…

Feat. J. Gotlib
02:58
12th International Congress on Myeloproliferative Neoplasms

73 y/o Male w/ Aggressive Systemic Mastocytosis: High-Sensitive Assa…

Feat. J. Gotlib
03:11
12th International Congress on Myeloproliferative Neoplasms

73 y/o Male w/ SM-AHM: Work Through Whether SM or AHN Is the Major C…

Feat. J. Gotlib
04:59
12th International Congress on Myeloproliferative Neoplasms

68 y/o Female w/ Systemic Mastocytosis with Chronic Myelomonocytic L…

Feat. J. Gotlib
02:43
12th International Congress on Myeloproliferative Neoplasms

28 y/o Female w/ Well-Differentiated Systemic Mastocytosis: Imatinib…

Feat. J. Gotlib
07:53
12th International Congress on Myeloproliferative Neoplasms

66 y/o Female w/ Systemic Mastocytosis Associated with CEL: Clinical…

Feat. J. Gotlib